24/7 Market News Snapshot 01 July, 2025 – MAIA Biotechnology, Inc. (NYSE:MAIA)

July 1, 2025

DENVER, Colo., 01 July, 2025 (www.247marketnews.com) – (NYSE:MAIA) are discussed in this article.
MAIA Biotechnology, Inc. (NYSE American: MAIA), a clinical-stage biopharmaceutical entity dedicated to developing targeted immunotherapies for cancer, demonstrated considerable market activity today. Opening at $2.00 and trading down to $1.98, the stock is reflecting a decline of approximately 10% from its previous close of $1.80, suggesting some investor profit-taking after a recent gain. Current trading volume stands at 1.21 million shares, indicating heightened interest. Analysts are closely watching key support levels around $1.80 and resistance near $2.00, as ongoing volatility may hint at evolving market sentiment toward the company.

In an exciting development, MAIA Biotechnology is set to participate in two esteemed poster presentations at the 49th Federation of European Biochemical Societies (FEBS) Congress, taking place from July 5-9, 2025. These presentations will feature innovative findings on MAIA’s lead telomere-targeting agent and next-generation therapeutic approaches.

One of the key presentations, titled “Telomere-targeting therapeutics RiboTHIO and THIO synergize with radiotherapy and immune checkpoint blockade to suppress lung tumor growth,” will be conducted by esteemed member Z. Günnur Dikmen, M.D., Ph.D., on July 7, 2025. This session aims to highlight the significant potential of MAIA’s therapies in enhancing the efficacy of existing cancer treatments.

Additionally, researcher Gamze Tuna will present findings on “The effects of telomerase mediated telomere-targeting novel drug candidate compounds on oxidative DNA damage and DNA repair on A549 cells,” during the same session. With these presentations, MAIA aims to solidify its position at the forefront of cancer therapeutics, demonstrating a commitment to improving treatment outcomes for patients battling this formidable disease.

Amidst the fluctuations of the stock market, MAIA remains focused on its clinical advancements, including promising results from the THIO-101 pivotal Phase 2 clinical trial investigating ateganosine for non-small cell lung cancer, reaffirming its dedication to innovation in cancer care.

Related news for (MAIA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.